यूरोपीय संघ - एस्टोनियाई - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiidi ained, välja arvatud kortikosteroidid - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

यूरोपीय संघ - एस्टोनियाई - EMA (European Medicines Agency)

teva gmbh - fremanezumab - migreenihäired - calcitonin gene-related peptide (cgrp) antagonists - ajovy on näidustatud migreeni profülaktika täiskasvanutel, kellel on vähemalt 4 migreen päeva kuus.

एस्टोनिया - एस्टोनियाई - Ravimiamet

viatris healthcare limited - ibuprofeen - suukaudne suspensioon - 40mg 1ml 150ml 1tk; 40mg 1ml 30ml 1tk; 40mg 1ml 100ml 1tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

pfizer europe ma eeig - somatropiin - süstelahuse pulber ja lahusti - 12mg 1tk; 12mg 5tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

pfizer europe ma eeig - somatropiin - süstelahuse pulber ja lahusti - 5,3mg 1tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

glaxosmithkline dungarvan limited - flutikasoon - ninasprei, suspensioon - 50mcg 1mõõtannus 60annus 1tk; 50mcg 1mõõtannus 120annus 1tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

sandoz pharmaceuticals d.d. - brinsolamiid - silmatilgad, suspensioon - 10mg 1ml 5ml 1tk; 10mg 1ml 5ml 3tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

sun pharmaceutical industries europe b.v. - meropeneem - süste-/infusioonilahuse pulber - 1g 10tk; 1g 1tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

sun pharmaceutical industries europe b.v. - meropeneem - süste-/infusioonilahuse pulber - 500mg 10tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

teva pharma b.v. - asitromütsiin - suukaudse suspensiooni pulber - 20mg 1ml 20ml 1tk